Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: JAPAN

Sector: Drug Manufacturers — Specialty and Generic

Takeda Pharmaceutical Company Limited is engaged in research and development, manufacturing, sales and marketing, and import and export of pharmaceutical drugs. The Company focuses on the core therapeutic areas of oncology, gastrointestinal, and central nervous system disease.


  • Good financial results growth rate 56.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (1.9%)
  • Dividend yield for the last twelve months 3.6%
  • Free cash flow yield 5.7% (LTM)
  • Share price is 31.8% higher than minimum and 2.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (8.5x vs 9.5x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: TAK
Share price, USD:  (0.0%)16.61
year average price 14.83  


year start price 13.54 2025-02-14

min close price 13.23 2025-10-30

max close price 16.61 2026-01-26

current price 16.61 2026-02-13
Common stocks: 3 130 324 000

Dividend Yield:  3.6%
FCF Yield LTM: 5.7%
EV / LTM EBITDA: 8.5x
EV / EBITDA annualized: 8.1x
Last revenue growth (y/y):  +12.8%
Last growth of EBITDA (y/y):  +99.3%
Historical revenue growth:  -1.9%
Historical growth of EBITDA:  +5.8%
EV / Sales: 2.7x
Margin (EBITDA LTM / Revenue): 32.0%

Target EV / EBITDA (hist percentile): 9.5x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 51 995
Net Debt ($m): 26 889
EV (Enterprise Value): 78 884
EBITDA LTM (млн $): 9 325
EV / LTM EBITDA: 8.5x
Price to Book: 1.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-30seekingalpha.com

Takeda Tests New Highs, But Struggles To Find Entyvio Successor

2026-01-29seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript

2026-01-29businesswire.com

Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

2026-01-13seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-18businesswire.com

Takeda's Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

2025-11-19globenewswire.com

Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery

2025-10-30seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

2025-10-30businesswire.com

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment.

2025-10-22seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Discusses Global Strategic Collaboration for Next-Generation Oncology Assets and ADC Molecules Transcript

2025-10-14reuters.com

US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q1
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-03-31
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-31 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2022-12-31 2022-09-30
acceptedDate 2025-10-30 06:05:26 2025-07-30 06:02:51 2025-06-25 06:23:25 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-06-26 06:07:45 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00 2022-06-29 06:05:31 2021-06-29 06:06:25
calendarYear 2025 2025 2025 2025 2024 2024 2024 2023 2023
period Q2 Q1 FY Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 1 112 796M 1 106 685M 4 581 551M 1 176 038M 1 207 990M 4 263 762M 1 111 186M 1 043 089M 1 058 618M 4 027 478M 1 096 551M 1 002 307M 3 569 006M 3 197 812M
costOfRevenue 380 061M 384 675M 1 580 217M 394 311M 549 785M 1 431 505M 379 481M 343 582M 321 114M 1 244 072M 335 973M 305 445M 1 106 846M 994 308M
grossProfit 732 735M 722 010M 3 001 334M 781 727M 658 205M 2 832 257M 731 705M 699 507M 737 504M 2 783 406M 760 578M 696 862M 2 462 160M 2 203 504M
grossProfitRatio 0.658 0.652 0.665 0.545 0.658 0.671 0.697 0.694 0.695
researchAndDevelopmentExpenses 161 482M 143 891M 730 227M 175 564M 168 463M 729 924M 187 381M 183 946M 162 741M 633 325M 174 629M 154 145M 526 087M 455 833M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 253 551M 255 885M 1 104 766M 268 282M 270 030M 1 053 819M 267 520M 252 952M 248 113M 997 309M 262 299M 248 734M 886 361M 875 663M
otherExpenses 248 707M 137 668M 823 755M 153 634M 216 214M 834 439M -1 210M 0 0 662 267M 176 660M 189 546M 588 867M 362 739M
operatingExpenses 663 740M 537 444M 2 658 748M 597 480M 654 707M 2 618 182M 665 290M 748 850M 568 933M 2 292 900M 613 588M 592 425M 2 001 315M 1 694 235M
costAndExpenses 1 043 801M 922 119M 4 238 965M 991 791M 1 041 661M 4 049 687M 1 044 771M 1 092 432M 890 047M 3 536 972M 949 561M 897 870M 3 108 161M 2 688 543M
interestIncome 44 396M 73 758M 19 638M 4 116M 30 677M 78M 21 789M -2 143M 26 455M 5 508M 41 679M 14 782M 4 591M 1 781M
interestExpense 83 138M 107 158M 137 311M 68 454M 59 691M 1 062M 66 568M 46 520M 59 575M 116 973M 79 749M 53 803M 122 432M 130 806M
depreciationAndAmortization 205 155M 181 636M 761 396M 192 452M 192 220M 644 461M 187 061M 182 696M 171 501M 664 400M 216 792M 181 741M 583 151M 559 671M
ebitda 316 467M 439 424M 1 210 512M 380 278M 384 548M 1 143 936M 314 889M 190 782M 366 109M 1 284 067M 363 782M 286 179M 1 183 213M 983 718M
ebitdaratio 0.284 0.397 0.323 0.318 0.283 0.183 0.346 0.332 0.286
operatingIncome 68 995M 184 566M 342 586M 184 247M 166 329M 214 075M 104 914M -49 341M 168 571M 490 505M 146 990M 104 438M 460 844M 509 269M
operatingIncomeRatio 0.062 0.167 0.157 0.138 0.094 -0.047 0.159 0.134 0.104
totalOtherIncomeExpensesNet -40 821M -33 936M -167 502M -64 875M -29 725M -161 284M 39 624M 2 025M -418M -115 415M -39 837M -39 889M -158 273M -143 034M
incomeBeforeTax 28 174M 150 630M 175 084M 119 372M 136 604M 52 791M 61 260M -95 980M 135 033M 375 090M 107 153M 64 549M 302 571M 366 235M
incomeBeforeTaxRatio 0.025 0.136 0.102 0.113 0.055 -0.092 0.128 0.098 0.064
incomeTaxExpense 39 903M 26 351M 66 941M 27 266M 41 304M -91 406M -44 496M -48 009M 45 627M 58 052M -11 996M 2 817M 72 405M -9 936M
netIncome -11 802M 124 243M 107 928M 92 046M 95 248M 144 067M 105 720M -48 030M 89 395M 317 017M 119 127M 61 742M 230 059M 376 005M
netIncomeRatio -0.011 0.112 0.078 0.079 0.095 -0.046 0.084 0.109 0.062
eps -3.74 39.7 34.17 0 59.94 46.05 67.38 -30.68 57.52 102.15 38.32 19.89 73.57 120.36
epsdiluted -3.74 39.12 0 59.94 66.7 -30.68 57.12 37.93 19.74
weightedAverageShsOut 3 155M 3 129M 3 211M 0 1 589M 3 129M 1 569M 1 565M 1 554M 3 104M 3 109M 3 105M 3 127M 3 124M
weightedAverageShsOutDil 3 155M 3 176M 3 211M 0 1 589M 3 161M 1 585M 1 565M 1 565M 3 140M 3 141M 3 127M 3 154M 3 147M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2025-06-25 2024-06-26 2023-06-28 2022-06-29 2021-06-29
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -117 673M -984M -111 192M -117 669M -128 653M
ebit 449 116M 499 475M 619 667M 600 062M 424 047M
nonOperatingIncomeExcludingInterest -106 530M -285 400M -129 162M -139 218M 85 222M
netIncomeFromContinuingOperations 108 143M 144 197M 317 038M 230 166M 376 171M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 107 928M 144 067M 317 017M 230 059M 376 005M
epsDiluted 33.62 45.58 100.97 72.94 119.48

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q1
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-03-31
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-31 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2022-12-31 2022-09-30
acceptedDate 2025-10-30 06:05:26 2025-07-30 06:02:51 2025-06-25 06:23:25 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-06-26 06:07:45 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00 2022-06-29 06:05:31 2021-06-29 06:06:25
calendarYear 2025 2025 2025 2025 2024 2024 2024 2023 2023
period Q2 Q1 FY Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 681 486M 350 008M 385 113M 859 015M 804 272M 457 800M 288 359M 318 051M 316 380M 533 530M 685 141M 798 137M 849 695M 966 222M
shortTermInvestments 58 192M 69 167M 20 476M 47 200M 359 493M 15 089M 29 045M 15 756M 52 229M 20 174M 41 467M 31 932M 25 305M 36 598M
cashAndShortTermInvestments 739 678M 419 175M 405 589M 906 215M 804 272M 472 889M 317 404M 333 807M 368 609M 553 704M 726 608M 830 069M 875 000M 1 002 820M
netReceivables 702 238M 679 531M 725 254M 721 056M 755 425M 697 610M 743 079M 788 066M 825 481M 681 694M 779 872M 800 536M 724 378M 812 714M
inventory 1 299 486M 1 240 676M 1 217 349M 1 206 431M 1 276 739M 1 209 869M 1 169 640M 1 155 866M 1 083 374M 986 457M 927 286M 953 450M 853 167M 753 881M
otherCurrentAssets 179 218M 173 740M 173 000M 220 311M 271 096M 178 212M 179 394M 178 219M 179 883M 176 101M 154 824M 155 636M 141 097M 143 478M
totalCurrentAssets 2 920 620M 2 513 122M 2 521 192M 3 054 013M 3 107 532M 2 558 580M 2 428 830M 2 462 066M 2 472 017M 2 397 956M 2 595 946M 2 745 616M 2 593 642M 2 712 893M
propertyPlantEquipmentNet 1 984 126M 1 956 269M 1 968 209M 1 887 620M 2 085 382M 1 989 777M 1 841 499M 1 894 136M 1 795 315M 1 691 229M 1 656 416M 1 760 327M 1 582 800M 1 453 917M
goodwill 5 431 698M 5 295 871M 5 324 430M 5 160 112M 5 733 710M 5 410 067M 5 111 287M 5 301 017M 5 182 128M 4 790 723M 4 690 949M 4 994 632M 4 407 749M 4 033 917M
intangibleAssets 3 299 225M 3 422 542M 3 631 560M 3 770 620M 4 366 147M 4 274 682M 4 097 022M 4 402 421M 4 514 084M 4 269 657M 3 765 757M 4 187 055M 3 818 544M 3 909 106M
goodwillAndIntangibleAssets 8 730 923M 8 718 413M 8 955 990M 8 930 732M 10 099 857M 9 684 749M 9 208 309M 9 703 438M 9 696 212M 9 060 380M 8 456 706M 9 181 687M 8 226 293M 7 943 023M
longTermInvestments 374 332M 347 120M 361 926M 277 314M 87 688M 430 608M 372 918M 416 364M 393 529M 378 857M 369 469M 425 766M 330 133M 348 350M
taxAssets 389 768M 401 058M 370 745M 338 304M 0 393 865M 316 689M 336 211M 375 522M 366 003M 359 393M 394 752M 362 539M 353 769M
otherNonCurrentAssets 70 531M 68 555M 70 282M 85 016M 847 224M 51 214M 54 703M 59 672M 60 143M 63 325M 66 774M 80 699M 82 611M 100 341M
totalNonCurrentAssets 11 549 680M 11 491 415M 11 727 152M 11 518 986M 13 120 151M 12 550 214M 11 794 118M 12 409 821M 12 320 721M 11 559 794M 10 908 758M 11 843 231M 10 584 377M 10 199 400M
otherAssets 0 0 0 1 000 000 0 -2M -1 000 000 2M 0 0 1 000 000 0 -1 000 000 0
totalAssets 14 470 300M 14 004 537M 14 248 344M 14 573 000M 16 227 683M 15 108 792M 14 222 947M 14 871 889M 14 792 738M 13 957 750M 13 504 705M 14 588 847M 13 178 018M 12 912 293M
accountPayables 438 985M 421 308M 308 450M 413 335M 468 882M 319 955M 483 666M 421 078M 440 924M 307 453M 381 109M 388 616M 295 934M 232 105M
shortTermDebt 293 858M 371 143M 548 939M 624 101M 438 743M 367 251M 370 292M 274 841M 416 860M 339 600M 372 019M 568 228M 203 993M 22 153M
taxPayables 122 907M 150 965M 0 141 439M 162 201M 109 906M 112 446M 130 218M 242 756M 232 377M 188 779M 189 568M 200 918M 145 203M
deferredRevenue 0 0 0 0 0 0 594 913M 787 875M 770 529M 0 0 0 0 0
otherCurrentLiabilities 1 283 905M 1 226 170M 1 348 544M 1 208 362M 1 395 376M 1 288 425M 833 297M 883 823M 873 428M 1 260 730M 1 483 681M 1 434 876M 1 224 521M 1 261 982M
totalCurrentLiabilities 2 139 655M 2 169 586M 2 506 521M 2 387 237M 2 465 202M 2 313 103M 2 282 168M 2 367 617M 2 501 741M 2 481 940M 2 236 809M 2 391 720M 2 145 730M 1 773 176M
longTermDebt 4 351 462M 4 134 799M 3 966 326M 4 427 092M 5 658 630M 4 476 501M 4 293 872M 4 404 363M 4 330 254M 4 042 741M 3 914 884M 4 168 417M 4 141 418M 4 613 218M
deferredRevenueNonCurrent 0 0 0 0 0 0 156 665M 153 936M 201 419M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 33 029M 33 514M 35 153M 46 619M 0 113 777M 133 036M 228 719M 269 549M 270 620M 388 681M 465 746M 451 511M 542 852M
otherNonCurrentLiabilities 814 465M 800 458M 804 365M 790 455M 304 618M 931 406M 614 599M 646 229M 568 106M 807 778M 787 833M 4 526 794M 755 836M 805 870M
totalNonCurrentLiabilities 5 198 956M 4 968 771M 4 805 844M 5 264 166M 5 963 248M 5 521 684M 5 198 172M 5 433 247M 5 369 328M 5 121 139M 5 091 398M 5 483 638M 5 348 765M 5 961 940M
otherLiabilities 0 0 0 0 1 000 000 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 616 388M 0 542 126M 574 874M 0 0 0 0 0 0
totalLiabilities 7 338 611M 7 138 357M 7 312 365M 7 651 403M 8 428 451M 7 834 787M 7 480 340M 7 800 864M 7 871 069M 7 603 079M 7 328 207M 7 875 358M 7 494 495M 7 735 116M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 1 694 759M 1 694 711M 1 694 685M 1 694 660M 1 676 596M 1 676 596M 1 676 543M 1 676 503M 1 676 411M 1 676 345M 1 676 334M 1 676 330M 1 676 263M 1 668 145M
retainedEarnings 1 148 658M 1 156 692M 1 187 586M 1 431 684M 1 338 192M 1 391 203M 1 396 838M 1 446 018M 1 490 097M 1 541 146M 1 507 720M 1 530 200M 1 479 716M 1 509 906M
accumulatedOtherComprehensiveIncomeLoss -3 595M 2 347 471M 2 351 915M 0 3 074 713M 2 509 310M 1 989 669M 2 287 968M 0 1 508 119M 0 0 934 173M 366 114M
othertotalStockholdersEquity 4 290 875M 1 666 385M 3 794 410M 1 708 916M 1 678 884M 1 659 863M 3 754 544M 2 991 924M 3 506 399M
totalStockholdersEquity 7 130 697M 6 865 259M 6 935 084M 6 920 754M 7 798 417M 7 273 264M 6 741 934M 7 070 352M 6 921 052M 6 354 122M 6 175 978M 6 712 929M 5 683 019M 5 173 037M
totalEquity 7 131 689M 6 866 180M 6 935 979M 6 921 597M 7 799 232M 7 274 005M 6 742 607M 7 071 025M 6 921 669M 6 354 671M 6 175 978M 6 712 929M 5 683 523M 5 177 177M
totalLiabilitiesAndStockholdersEquity 14 470 300M 14 004 537M 14 573 000M 16 227 683M 14 222 947M 14 871 889M 14 792 738M 13 504 705M 14 588 847M
minorityInterest 992M 921M 895M 843M 815M 741M 673M 673M 617M 549M 520M 0 504M 4 140M
totalLiabilitiesAndTotalEquity 14 470 300M 14 004 537M 14 248 344M 14 573 000M 16 227 683M 15 108 792M 14 222 947M 14 871 889M 14 792 738M 13 957 750M 13 504 705M 14 588 847M 13 178 018M 12 912 293M
totalInvestments 432 524M 416 287M 382 402M 324 514M 447 181M 445 697M 401 963M 432 120M 445 758M 399 031M 410 936M 457 698M 355 438M 384 948M
totalDebt 4 645 320M 4 505 942M 4 515 265M 5 051 193M 5 480 985M 4 843 752M 4 664 164M 4 679 204M 4 747 114M 4 382 341M 4 286 903M 4 736 645M 4 345 411M 4 635 371M
netDebt 3 963 834M 4 155 934M 4 130 152M 4 192 178M 4 676 713M 4 385 952M 4 375 805M 4 361 153M 4 430 734M 3 848 811M 3 601 762M 3 938 508M 3 495 716M 3 669 149M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2025-06-25 2024-06-26 2023-06-28 2022-06-29 2021-06-29
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 651 415M 612 439M 575 431M 617 518M 707 487M
otherReceivables 73 839M 85 171M 106 262M 106 859M 105 227M
prepaids 0 0 0 0 0
totalPayables 609 038M 657 427M 881 610M 717 216M 489 041M
otherPayables 300 588M 337 472M 574 157M 421 282M 256 936M
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock -74 815M -51 259M -100 317M -116 007M -59 552M
additionalPaidInCapital 1 775 713M 1 747 414M 1 728 830M 1 708 873M 1 688 424M
otherTotalStockholdersEquity 0 0 -1 000 000 1 000 000 0

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q1 2021 q1
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-03-31 2021-03-31
symbol TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK TAK
reportedCurrency JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY JPY
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-07-30 2024-10-31 2024-05-29 2024-02-02 2023-09-30 2023-06-23 2022-12-31 2022-09-30
acceptedDate 2025-10-30 06:05:26 2025-07-30 06:02:51 2025-06-25 06:23:25 2024-10-31 06:28:39 2024-05-29 06:24:59 2024-06-26 06:07:45 2024-02-02 06:16:40 2023-09-30 00:00:00 2023-06-23 06:13:42 2023-06-28 06:07:10 2022-12-30 19:00:00 2022-09-29 20:00:00 2022-06-29 06:05:31 2021-06-29 06:06:25
calendarYear 2025 2025 2025 2025 2024 2024 2024 2023 2023
period Q2 Q1 FY Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -11 729M 124 279M 107 928M 92 107M 95 299M 144 067M 105 755M -47 970M 89 406M 317 038M 119 150M 61 732M 230 166M 376 171M
depreciationAndAmortization 184 982M 181 636M 761 396M 192 452M 192 220M 728 002M 187 061M 182 696M 171 501M 664 400M 176 880M 167 827M 583 151M 559 671M
deferredIncomeTax 39 903M 26 351M 0 27 266M 41 304M -91 406M -44 496M -48 009M 45 627M 58 052M -11 996M 2 817M 72 405M -9 936M
stockBasedCompensation 18 731M 16 531M 72 867M 21 554M 15 386M 70 871M 18 706M 18 535M 15 442M 60 672M 16 488M 17 043M 43 374M 37 663M
changeInWorkingCapital 21 938M -33 701M -52 254M -70 810M -189 979M -256 003M -166 022M 1 590M -150 947M -25 264M 51 304M -31 491M 98 605M 275 781M
accountsReceivables -9 797M 48 083M -58 959M -10 035M -47 744M 15 104M 14 288M 17 292M 0 75 127M 0 0 127 294M -9 316M
inventory -28 962M -13 069M -34 973M -41 139M -10 079M -115 743M -50 552M -49 349M -28 589M -79 155M -18 462M -6 660M -46 148M 25 978M
accountsPayables 0 0 0 0 -37 455M -9 895M 70 266M -15 023M 0 -53 135M 0 0 75 549M 210 020M
otherWorkingCapital 60 697M -68 715M 41 678M -19 636M -94 701M -145 469M -200 024M 48 670M -122 358M 31 899M 69 766M -24 831M -58 090M 49 099M
otherNonCashItems 124 403M -99 673M 167 245M 18 394M 16 074M 120 813M 45 447M 92 063M -78 629M -97 742M 26 403M 3 065M 95 404M -228 419M
netCashProvidedByOperatingActivities 378 228M 215 423M 1 057 182M 280 963M 170 304M 716 344M 146 451M 198 905M 92 400M 977 156M 378 229M 220 993M 1 123 105M 1 010 931M
investmentsInPropertyPlantAndEquipment -40 095M -47 913M -200 795M -49 473M -57 441M -175 420M -77 124M -70 043M -269 237M -633 689M -50 624M -40 609M -186 037M -236 468M
acquisitionsNet 417M 29 291M 0 5 389M 0 -4 735M -26 250M -7M 372M 7 958M 0 0 -21 476M 530 388M
purchasesOfInvestments -1 550M -215M 0 -10 052M -31 672M -40 066M -2 460M -1 590M -674M -10 151M -747M -1 761M -8 341M -12 596M
salesMaturitiesOfInvestments 2 882M 1 128M 0 17 798M 5 317M 8 021M 458M 88M 543M 22 254M 2 153M 12 222M 16 921M 74 604M
otherInvestingActivites -9 787M -15 484M -38 793M -72 897M 30 107M 10 973M 2 466M 2 528M 2 942M
netCashUsedForInvestingActivites -48 133M -33 193M -75 131M -156 693M -75 269M -60 579M -266 530M -46 690M -27 206M
debtRepayment 36 555M 22M -69 547M 429 613M -96 507M -157 070M -110 634M -266 199M -10 767M
commonStockIssued 0 0 0 0 0 0 190 185M 0 0
commonStockRepurchased 2M -51 603M -51 860M 0 -1 882M -2 326M 0 0 -2 326M -26 929M 0 0 -77 531M -2 141M
dividendsPaid -8 787M -145 295M -9 199M -138 110M -138 251M -9 065M -130 746M -128 990M -11 134M
otherFinancingActivites -39 751M -18 024M -31 299M 26 760M 136 998M 25 480M -4 257M -39 766M -29 975M
netCashUsedProvidedByFinancingActivities -11 981M -214 900M -110 045M 316 381M -97 760M -140 655M -57 778M -434 955M -51 876M
effectOfForexChangesOnCash 13 364M -2 435M -11 385M -41 784M 17 220M 26 204M -3 115M 4 000M 14 759M 22 929M -9 579M 10 235M 28 758M 12 501M
netChangeInCash 331 478M -35 105M -72 687M 54 003M 599 082M -75 730M -29 692M 1 671M -217 150M -316 165M -112 996M 152 146M -116 527M 328 608M
cashAtEndOfPeriod 681 486M 350 008M 385 113M 859 015M 804 272M 457 800M 288 359M 318 051M 316 380M 533 530M 685 141M 798 137M 849 695M 966 222M
cashAtBeginningOfPeriod 350 008M 385 113M 457 800M 805 012M 205 190M 533 530M 318 051M 316 380M 533 530M 849 695M 798 137M 645 991M 966 222M 637 614M
operatingCashFlow 378 228M 215 423M 1 057 182M 280 963M 159 375M 716 344M 146 451M 198 905M 92 400M 977 156M 378 229M 220 993M 1 123 105M 1 010 931M
capitalExpenditure -52 825M -75 068M -200 795M -92 452M -137 798M -480 730M -77 124M -70 043M -269 237M -633 689M -50 624M -40 609M -186 037M -236 468M
freeCashFlow 325 403M 140 355M 856 387M 188 511M 21 577M 235 614M 69 327M 128 862M -176 837M 343 467M 327 605M 180 384M 937 068M 774 463M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link
filingDate 2025-06-25 2024-06-26 2023-06-28 2022-06-29 2021-06-29
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -166 265M -251 662M 6 526M 808M 37 602M
netCashProvidedByInvestingActivities -367 060M -463 862M -607 102M -198 125M 393 530M
netDebtIssuance -314 314M 1 513M -285 071M -600 477M -511 461M
longTermNetDebtIssuance -341 804M -275 487M -325 071M -600 475M -511 461M
shortTermNetDebtIssuance 27 490M 277 000M 40 000M -2M 0
netStockIssuance -51 860M -2 326M -26 929M -77 531M -2 141M
netCommonStockIssuance -51 860M -2 326M -26 929M -77 531M -2 141M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid -302 498M -287 188M -279 416M -283 665M -283 357M
commonDividendsPaid -302 498M -287 188M -279 416M -283 665M -283 357M
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -82 753M -66 415M -117 732M -108 592M -291 395M
netCashProvidedByFinancingActivities -751 425M -354 416M -709 148M -1 070 265M -1 088 354M
incomeTaxesPaid 0 0 0 0 0
interestPaid 112 984M 0 0 0 0

Earning call transcript

2025 q4
2026-01-29 ET (fiscal 2026 q3)
2025 q1
2025-05-09 ET (fiscal 2024 q4)
2024 q4
2025-01-30 ET (fiscal 2024 q3)
2024 q3
2024-10-31 ET (fiscal 2025 q2)
2024 q2
2024-08-02 ET (fiscal 2025 q1)
2024 q1
2024-05-09 ET (fiscal 2023 q4)
2023 q3
2023-10-27 ET (fiscal 2023 q2)
2023 q2
2023-07-27 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2023 q3)
2022 q1
2022-05-12 ET (fiscal 2022 q4)
2021 q4
2022-02-03 ET (fiscal 2022 q3)
2021 q3
2021-10-29 ET (fiscal 2022 q2)
2021 q2
2021-07-31 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 6
2026-01-29 06:02 ET
Takeda Pharmaceutical reported for 2025 q4
SEC form 6
2026-01-29 06:02 ET
Takeda Pharmaceutical published news for 2025 q4
SEC form 6
2025-12-18 11:03 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-12-08 11:02 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-11-28 06:08 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-11-28 06:08 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-10-30 10:12 ET
Takeda Pharmaceutical reported for 2025 q3
SEC form 6
2025-10-30 10:05 ET
Takeda Pharmaceutical reported for 2025 q3
SEC form 6
2025-10-30 10:05 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-10-30 10:00 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-10-01 13:20 ET
Takeda Pharmaceutical published news for 2025 q3
SEC form 6
2025-09-25 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-09-08 10:18 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-09-08 10:18 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-31 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-31 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-30 10:02 ET
Takeda Pharmaceutical reported for 2025 q2
SEC form 6
2025-07-30 10:02 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-14 10:05 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-09 10:01 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-09 10:01 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-08 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-02 14:33 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-07-01 10:03 ET
Takeda Pharmaceutical published news for 2025 q2
SEC form 6
2025-06-30 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-30 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 20
2025-06-25 10:23 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-25 10:03 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-25 10:02 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-12 10:04 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-10 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-06 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-02 10:06 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-06-02 10:01 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:27 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:27 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:20 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:20 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-28 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-14 10:03 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:19 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:19 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-05-08 10:14 ET
Takeda Pharmaceutical reported for 2025 q1
SEC form 6
2025-05-08 10:14 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-22 10:08 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-14 10:12 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-04-01 10:07 ET
Takeda Pharmaceutical published news for 2025 q1
SEC form 6
2025-03-26 10:01 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-13 10:00 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-03 11:46 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-03-03 11:03 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-02-13 11:06 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:29 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:28 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:25 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:24 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2025-01-30 06:23 ET
Takeda Pharmaceutical reported for 2024 q4
SEC form 6
2025-01-30 06:23 ET
Takeda Pharmaceutical published news for 2024 q4
SEC form 6
2024-12-02 06:00 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-12-02 06:00 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-10-31 06:28 ET
Takeda Pharmaceutical reported for 2024 q3
SEC form 6
2024-10-31 06:21 ET
Takeda Pharmaceutical reported for 2024 q3
SEC form 6
2024-10-31 06:21 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-10-31 06:19 ET
Takeda Pharmaceutical published news for 2024 q3
SEC form 6
2024-09-26 06:01 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-31 06:02 ET
Takeda Pharmaceutical reported for 2024 q2
SEC form 6
2024-07-31 06:02 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-10 06:04 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-10 06:04 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-09 06:05 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-05 11:28 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-02 06:20 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-01 06:33 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-07-01 06:33 ET
Takeda Pharmaceutical published news for 2024 q2
SEC form 6
2024-06-26 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-26 06:01 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 20
2024-06-26 00:00 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-17 06:46 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-11 06:23 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-10 06:10 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-07 06:07 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-07 06:04 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-03 06:45 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-06-03 06:26 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:29 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:24 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-29 06:24 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-05-21 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-19 06:12 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-19 06:12 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-04-15 06:02 ET
Takeda Pharmaceutical published news for 2024 q1
SEC form 6
2024-03-27 06:34 ET
Takeda Pharmaceutical published news for 2023 q4
SEC form 6
2024-01-16 06:01 ET
Takeda Pharmaceutical published news for 2023 q4
SEC form 6
2023-12-14 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-12-14 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-11-30 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-11-30 06:01 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-26 06:22 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-26 06:20 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-18 06:21 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-18 06:20 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-10-02 06:17 ET
Takeda Pharmaceutical published news for 2023 q3
SEC form 6
2023-09-28 06:17 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-09-11 06:50 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-27 06:05 ET
Takeda Pharmaceutical reported for 2023 q2
SEC form 6
2023-07-12 06:07 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-06 06:18 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-03 06:02 ET
Takeda Pharmaceutical published news for 2023 q2
SEC form 6
2023-06-28 06:07 ET
Takeda Pharmaceutical reported for 2023 q1
SEC form 6
2023-06-28 06:02 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-28 06:00 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 20
2023-06-28 00:00 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-23 06:13 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-23 06:10 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-09 06:03 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-06-01 06:02 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:20 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:19 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:14 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-30 06:11 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-11 06:10 ET
Takeda Pharmaceutical published news for 2023 q1
SEC form 6
2023-05-11 06:07 ET
Takeda Pharmaceutical reported for 2023 q1
SEC form 6
2023-03-30 06:19 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-20 06:17 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-16 06:03 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-03-01 06:03 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-10 06:00 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-09 06:00 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-02-07 06:05 ET
Takeda Pharmaceutical reported for 2022 q4
SEC form 6
2023-02-02 06:04 ET
Takeda Pharmaceutical reported for 2022 q4
SEC form 6
2023-01-10 06:01 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2023-01-05 06:46 ET
Takeda Pharmaceutical published news for 2022 q4
SEC form 6
2022-12-21 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-12-13 07:00 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-12-08 06:46 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-11-30 06:28 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-11-04 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-27 06:01 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-14 07:36 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-10-04 06:06 ET
Takeda Pharmaceutical published news for 2022 q3
SEC form 6
2022-08-23 06:13 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-08-04 06:07 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-28 06:09 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-11 06:05 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-07-05 06:09 ET
Takeda Pharmaceutical published news for 2022 q2
SEC form 6
2022-06-29 06:05 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:02 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:01 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-29 06:01 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 20
2022-06-29 00:00 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-24 06:08 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-10 06:00 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-06-01 06:08 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:20 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:18 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:14 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:11 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-31 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-12 06:05 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-11 06:11 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-05-11 06:06 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-19 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-14 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-13 06:41 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-01 06:14 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-04-01 06:07 ET
Takeda Pharmaceutical published news for 2022 q1
SEC form 6
2022-03-22 06:13 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-03-14 06:08 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-03-01 06:19 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-14 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-10 06:03 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:18 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:11 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-02-03 06:09 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-13 06:01 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-11 06:04 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-11 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2022-01-05 06:02 ET
Takeda Pharmaceutical published news for 2021 q4
SEC form 6
2021-12-27 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-16 06:02 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-14 06:01 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-12-01 06:00 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-30 06:04 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-12 06:01 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-05 06:02 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-01 06:37 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-11-01 06:04 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-28 06:26 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-28 06:12 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-08 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-06 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-10-01 06:03 ET
Takeda Pharmaceutical published news for 2021 q3
SEC form 6
2021-09-07 06:05 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-09-07 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-09-01 08:01 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-30 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-26 06:06 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-18 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:10 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:06 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-06 06:03 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-08-02 06:15 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-30 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-20 06:05 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-19 06:02 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-08 06:21 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-07-02 06:07 ET
Takeda Pharmaceutical published news for 2021 q2
SEC form 6
2021-06-29 07:38 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:06 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:03 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:02 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-29 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 20
2021-06-29 00:00 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-21 06:05 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-06-21 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:07 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:04 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:03 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-28 06:01 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-26 20:55 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-21 06:04 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:28 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:24 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:20 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:15 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-11 06:08 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-05-10 06:06 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-06 06:29 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-02 08:02 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-04-01 06:15 ET
Takeda Pharmaceutical published news for 2021 q1
SEC form 6
2021-03-31 06:11 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-31 06:09 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-11 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-03-05 06:00 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-26 06:01 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-24 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-12 06:04 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-04 06:07 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-02-04 06:05 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2021-01-21 06:08 ET
Takeda Pharmaceutical published news for 2020 q4
SEC form 6
2020-12-17 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-12-08 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-30 06:18 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-24 06:06 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-11-10 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:04 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:02 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-29 06:01 ET
Takeda Pharmaceutical published news for 2020 q3
SEC form 6
2020-10-09 06:11 ET
Takeda Pharmaceutical published news for 2020 q3